Teva Canada intros generic Concerta
Teva Canada has launched its generic Concerta (methylphenidate hydrochloride). The extended-release tablet is indicated to treat attention deficit hyperactivity disorder in patients ages 6 years and older.
“We’ve heard from healthcare providers, ADHD patients and their parents about the need for an affordable alternative to Concerta that works in the same way and at the same time,” Teva Canada senior director of commercial management David Boughner said. “We’re pleased to offer patients ACT Methylphenidate ER as a bioequivalent modified release product that allows for a biphasic drug release profile after oral administration. In addition, the pharmacokinetic parameters mimic the concentration-time release profile of Concerta.”
ADHD is the most common neurodevelopmental disorder, affecting roughly 1-in-20 children, according to Portico, Canada’s mental health and addiction network.
Teva Canada’s generic Concerta will be available in 18-, 27-, 36- and 54-mg tablets. The once-daily drug had a Canadian market size of roughly $175 million for the 12 months ended January 2018, according to IQVIA data.
Sun Pharma’s Ilumya gets FDA approval
The Food and Drug Administration has approved Sun Pharma’s Ilumya (tildrakizumab-asmn). The biologic drug is indicated to treat moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
“With the approval of Ilumya and our long-standing commitment in dermatology, we are focused on making a difference for people living with moderate-to-severe plaque psoriasis,” Sun Pharma president and CEO, North America, Abhay Gandhi said. “We are committed to working with all relevant stakeholders to make Ilumya available to appropriate people with plaque psoriasis.”
Ilumya is meant to be administered in a 100-mg dose every 12 weeks after two intial doses four weeks apart.
West-Ward launches first Norvir generic
West-Ward Pharmaceuticals, the U.S. subsidiary of Hikma Pharmaceuticals, has introduced the first generic of Norvir (ritonavir) tablets. The company’s generic treatment for HIV in combination with other antiretroviral agents will be entitled to 180 days of market exclusivity, West-Ward said.
“We are very excited to be launching ritonavir tablets,” Hikma generics president Brian Hoffman said. “This is an exciting product which demonstrates the successful execution of our strategy to develop differentiated products. We will be launching ritonavir with additional patient support and co-pay assistance to ensure more people are able to access this life-saving medicine.”
West-Ward said that as part of the launch, it was engaging advocacy organizations to gain an understanding of the best way to support patients and providers. It also will launch an education and awareness campaign that includes a website and direct communication.
West-Ward’s generic Norvir will be available in 100-mg dosage strength. The generic Norvir is launching into a market that IQVIA data said saw $208.5 million in sales for the 12 months ended December 2017.